3 results
Approved WMOCompleted
To determine whether a second IVIg course in GBS patients with a poor prognosis improves functional outcome after 4 weeks.
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
Approved WMOCompleted
Effect on bone mineral density.